Pure BioScience Reports Fiscal 2026 Revenue of $2.318 Million
Fiscal 2026 revenue rose 5.3% from fiscal 2025. Net loss widened to $2.483 million from $2.399 million, while diluted loss per share was unchanged from the prior year.
Pure BioScience reported fiscal 2026 revenue of $2.318 million, up 5.3% from fiscal 2025, while its net loss widened to $2.483 million from $2.399 million. Diluted loss per share was $(0.02), unchanged from the prior year.Financial HighlightsBusiness HighlightsOriginal SEC Filing: PURE BIOSCIENCE…